Loading
NASDAQHealthcareBiotechnology
Latest quote
$6.04
−$0.18 · -2.89%
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Previous close
$6.04
−$0.18 · -2.89%
Regular session · ET · Market data may be delayed.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Day range
Current $6.04
52-week range
Current $6.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
54
Mixed
Risk
63
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Day range
Current $6.04
52-week range
Current $6.04
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 5.42M USD | 5.99M USD | 5.7M USD | 4.32M USD | 2.84M USD |
| Selling, general, and administrative | 5.98M USD | 4.12M USD | 4.23M USD | 5.96M USD | 4.6M USD |
| Operating expenses | 11.4M USD | 10.11M USD | 9.93M USD | 10.29M USD | 7.44M USD |
| Interest income | — | — | — | 2K USD | 2K USD |
| Interest expense | 194K USD | — | — | 5K USD | — |
| Depreciation and amortization | 146K USD | — | — | — | — |
| Operating income | −11.4M USD | −10.11M USD | −9.93M USD | −10.29M USD | −7.44M USD |
| Net income | −12.88M USD | −9.83M USD | −9.29M USD | −10.08M USD | −7.44M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 31, 2026 | 1:9 | — | — |
Stock split | Mar 10, 2026 | 1:3 | — | — |
Stock split | Jun 13, 2025 | 1:6 | — | — |
Stock split | Aug 10, 2022 | 1:15 | — | — |
Stock split | Jun 21, 2019 | 1:8 | — | — |
Effective Aug 31, 2026
1:9
Effective Mar 10, 2026
1:3
Effective Jun 13, 2025
1:6
Effective Aug 10, 2022
1:15
Effective Jun 21, 2019
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
